What was the major announcement from EMVision Medical Devices (ASX:EMV) regarding its FDA trial?

EMVision is expanding its pivotal FDA De Novo trial for its "emu" portable brain-imaging device to include the detection of acute ischaemia (blood clots). Previously, the trial focused primarily on haemorrhage (bleeding) detection.

How does the trial expansion affect EMVision’s (ASX:EMV) existing goals for haemorrhage detection?

Management expects the modifications to the trial to be modest and incremental, meaning they should not derail existing progress. The primary objective for haemorrhage detection remains a sensitivity and specificity of greater than 80%.

What is the current status of the EMVision (ASX:EMV) pivotal trial recruitment?

As of May 2026, EMVision has recruited over 125 patients for its pivotal trial with no reported device-related adverse events. This milestone suggests the technology is performing safely in a clinical environment.

Is EMVision (ASX:EMV) adequately funded to complete its clinical trials?

EMVision reported a solid cash position of $18.4 million as of March 31, 2026. This balance was recently supported by an additional $0.4 million non-dilutive payment from Cooperative Research Centres Projects (CRC-P) funding.

What are the main risks associated with adding ischaemia detection to the trial?

Detecting acute ischaemia is generally considered more complex than identifying a haemorrhage, which introduces new regulatory and execution risks. There are currently no performance results available for the ischaemia endpoint, so its success is speculative.

What is the "emu" device and how does it fit into EMVision’s long-term strategy?

The "emu" is a portable, non-invasive brain-imaging device designed to provide rapid point-of-care stroke diagnosis. EMVision’s strategy is to disrupt the traditional imaging market by moving diagnostic power from stationary hospital scanners to the bedside or regional clinics.

EMVision expands FDA trial for Ischaemia detection

Written by Isaac FrancisPublished May. 11 2026Last Updated May. 11 2026

EMVision Medical Devices (ASX:EMV) announced an expansion of its pivotal FDA De Novo trial, now incorporating acute ischaemia detection alongside its primary focus on haemorrhage identification.

The move aims to broaden the clinical utility and market potential of the company’s portable brain-imaging device, the "emu", by streamlining the regulatory pathway for multiple indications.

By leveraging existing trial infrastructure and patient cohorts, EMVision expects the modifications to be modest and incremental, ensuring that the primary objective for haemorrhage detection—maintaining a sensitivity and specificity of over 80%—remains on track.

The trial’s momentum continues to build, with recruitment surpassing 125 patients and no device-related adverse events reported.

Full enrolment is anticipated by late 2026 or early 2027, with sequential cohort readouts expected shortly thereafter.

The company remains in a robust position, reporting cash reserves of $18.4 million as of March 31, further bolstered by a recent $0.4 million non-dilutive payment from CRC-P funding.

Simultaneously, progress is accelerating on the regional benefit study, with ethics approval expected in the second half of 2026.

The study is designed to demonstrate how the technology can assist underserved regional patients via telehealth, providing faster stroke diagnosis and management.

At the time of reporting, EMVision Medical Devices’ share price was $1.90.